Change over period: —
NSE · GLAND
GLAND
-4.6% from the 52-week high · +102.3% above the low
Gland Pharma Ltd. manufactures pharmaceutical ingredients and injectable formulations. The company is headquartered in Hyderabad, Telangana. The company went IPO on 2020-11-20. The firm specializes in complex injectables and is engaged in the sterile injectables, oncology, and ophthalmology segments. The firm provides contract development, own development, dossier preparation and filing, technology transfer and manufacturing across a variety of delivery systems. Its products are available in liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags, and drops. Its key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. Its therapeutic products categories include Anti Malarials, Anti-Infectives, Anti-Neoplastics, Blood Related, Cardiac, Gastrointestinal, Gynaecological, Hormones, Neuro / Cns, Ophthal / Otologicals, Pain/Analgesics, Respiratory and Vitamins / Minerals / Nutrients. Its products are sold across various countries, which include United States, Europe, Canada, and others.
The short version. GLAND reported revenue of ₹1,834 crore for Sep 2026, up 23.3% from a year earlier. Net profit was ₹291 crore (up 58.2% year on year). Return on equity was 9.9% in Mar 2026. Promoter holding was 45.75% in Sep 2026, down 6.08 points over 8 quarters.
1 · The price
How has the stock traded?
GLAND trades 4.6% below its 52-week high and 102.3% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹1,834 cr.
Sep 2026 net profit of ₹291 cr.
3.5 pts higher than a year earlier.
Revenue compounded at 20.4% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1834 | 1800 | 1743 | 1695 | 1487 | 1506 | 1425 | 1384 |
| Net profit | 291 | 317 | 367 | 261 | 184 | 215 | 187 | 205 |
| Net margin % | 15.9 | 17.6 | 21.0 | 15.4 | 12.4 | 14.3 | 13.1 | 14.8 |
| EPS (₹) | 17.62 | 19.21 | 22.26 | 15.87 | 11.15 | 13.08 | 11.32 | 12.42 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Revenue | 6431 | 5617 | 5665 | 3625 | 4401 | 3463 |
| Net profit | 1027 | 699 | 772 | 781 | 1212 | 997 |
| Net margin % | 16.0 | 12.4 | 13.6 | 21.5 | 27.5 | 28.8 |
| EPS (₹) | 62.35 | 42.4 | 46.9 | 47.42 | 73.75 | 60.94 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 9.9% in Mar 2026; debt to equity is 0.02.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 9.9 | 7.6 | 8.8 | 9.8 |
| Return on capital % | 13.7 | 11.4 | 12.5 | 13.2 |
| EBITDA margin % | 28.5 | 25.4 | 25.8 | 31.3 |
| Net margin % | 15.2 | 12.0 | 13.2 | 20.2 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 20.4% | 13.4% |
| Profit CAGR | 9.6% | 0.6% |
4 · The owners
Who holds it, and are they adding?
Down 6.08 pts over 8 quarters.
Up 5.32 pts over 8 quarters.
Down 1.59 pts over 8 quarters.
+42 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 51.83 | 51.83 | 51.83 | 51.83 | 51.83 | 51.83 | 51.77 | 45.75 | -6.08 |
| FII | 5.04 | 6.9 | 7.39 | 7.91 | 7.58 | 7.3 | 8.74 | 10.36 | +5.32 |
| DII | 34.8 | 33.27 | 32.85 | 32.64 | 32.98 | 33.35 | 30.44 | 33.21 | -1.59 |
| Public | 8.33 | 7.99 | 7.93 | 7.63 | 7.61 | 7.52 | 9.05 | 10.66 | +2.33 |
Mutual fund holdings · Oct 2026
177 schemes hold this stock
135 the month before.
- DSP Healthcare Fund6.61% of NAV
- UTI - MNC Fund4.52% of NAV
- UTI - Healthcare Fund3.89% of NAV
- ADITYA BIRLA SUN LIFE MNC FUND3.82% of NAV
- TATA NIFTY MIDSMALL HEALTHCARE INDEX FUND3.72% of NAV
- Motilal Oswal Nifty MidSmall Healthcare Index Fund3.71% of NAV
- SAMCO ELSS TAX SAVER FUND3.66% of NAV
- SAMCO SMALL CAP FUND3.53% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for GLAND are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about GLAND
What is the GLAND share price?
GLAND (GLAND) last closed at ₹3,286.80, up 1.74% on the day. Its 52-week range is ₹1,596.80 to ₹3,385.90.
What is the market cap of GLAND?
GLAND has a market capitalisation of about ₹53,281 crore. Its price-to-earnings ratio is 43.2.
How are GLAND's latest results?
GLAND reported revenue of ₹1,834 crore for Sep 2026, up 23.3% from a year earlier. Net profit was ₹291 crore (up 58.2% year on year). Return on equity was 9.9% in Mar 2026. Promoter holding was 45.75% in Sep 2026, down 6.08 points over 8 quarters.
Who owns GLAND?
As of Sep 2026, shareholding was: Promoter 45.75%, FII 10.36%, DII 33.21%, Public 10.66%.
How many mutual funds hold GLAND?
177 mutual fund schemes held GLAND in October 2026. That compares with 135 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 14 Aug 2025 · Final Dividend - Rs. 18
- 16 Aug 2024 · Final Dividend - Rs. 20
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.